HC Wainwright Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANXFree Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock.

A number of other research firms also recently commented on GANX. Oppenheimer reissued an outperform rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Wednesday, August 14th. Chardan Capital reissued a buy rating and issued a $6.00 target price on shares of Gain Therapeutics in a report on Friday, August 9th.

Get Our Latest Research Report on GANX

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $2.07 on Wednesday. Gain Therapeutics has a 1-year low of $0.89 and a 1-year high of $5.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.84 and a quick ratio of 2.84. The stock has a fifty day moving average price of $1.41 and a 200 day moving average price of $1.95. The company has a market cap of $52.85 million, a PE ratio of -1.59 and a beta of 0.42.

Gain Therapeutics (NASDAQ:GANXGet Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). Sell-side analysts forecast that Gain Therapeutics will post -1.05 EPS for the current year.

Insider Transactions at Gain Therapeutics

In related news, Chairman Khalid Islam acquired 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average price of $1.00 per share, for a total transaction of $50,000.00. Following the transaction, the chairman now owns 50,000 shares in the company, valued at $50,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.70% of the company’s stock.

Institutional Trading of Gain Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter valued at about $66,000. Renaissance Technologies LLC grew its holdings in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the period. Finally, Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter valued at about $422,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

(Get Free Report)

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

See Also

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.